Drugs / NAVAMEPENT
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02329743 | Dec 2014 → Sep 2015 | cataract | A.T. Resolve SARL | Completed | No outcome recorded |
| Phase 2 | NCT01675570 | Aug → Nov 2012 | dry eye syndrome | C.T. Development America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01639846 | Jul → Aug 2012 | conjunctivitis | C.T. Development America, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00799552 | Nov 2008 → May 2009 | dry eye syndrome | Resolvyx Pharmaceuticals, Inc | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NAVAMEPENT | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314965 ↗ |
| Known as | RX-10045 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00799552 ↗ |
| Modality | Small molecule | — CHEMBL5314965 ↗ |
| Route | Other | “One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.” NCT01675570 ↗ |